REFERENCES
1. Wilson C, Coleman R. Adjuvant bone-targeted therapies for postmenopausal breast cancer. JAMA Oncol 2016;2:423-4.
2. Body JJ, Terpos E, Tombal B, Hadji P, Arif A, et al. Bone health in the elderly cancer patient: a SIOG position paper. Cancer Treat Rev 2016;51:46-53.
3. Wong M, Pavlakis N. Optimal management of bone metastases in breast cancer patients. Breast Cancer (Dove Med Press) 2011;3:35-60.
4. Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 2014;15:997-1006.
5. Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007;99:322-30.
6. Hiraga T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001;61:4418-24.
7. Zekri J, Mansour M, Karim SM. The anti-tumour effects of zoledronic acid. J Bone Oncol 2014;3:25-35.
8. Suominen MI, Rissanen JP, Käkönen R, Fagerlund KM, Alhoniemi E, et al. Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis. J Natl Cancer Inst 2013;105:908-16.
9. Junankar S, Shay G, Jurczyluk J, Ali N, Down J, et al. Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. Cancer Discov 2015;5:35-42.
10. Rogers TL, Wind N, Hughes R, Nutter F, Brown HK, et al. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models. Cell Oncol (Dordr) 2013;36:505-14.
11. Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res 2008;14:4658-66.
12. Brown HK, Ottewell PD, Evans CA, Coleman RE, Holen I. A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts. J Bone Oncol 2012;1:47-56.
13. Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008;100:1167-78.
14. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, et al. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 2009;8:2821-32.
15. Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, et al. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 2010;126:522-32.
16. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-9.
17. Arguello F, Frantz CN, Baggs RB. Experimental bone and bone marrow metastasis in laboratory animals. J Natl Cancer Inst 1990;82:1069-70.
18. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995;55:3551-7.
19. Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, et al. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 2009;44:908-16.
20. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010;102:1099-105.
21. Horiguchi J, Hasegawa Y, Miura D, Ishikawa T, Hayashi M, et al. A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer. J Clin Oncol 2013;31:1029.
22. Fasching PA, Jud SM, Hauschild M, Kümmel S, Schütte M, et al. FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. BMC Cancer 2014;14:66.
23. Charehbili A, van de Ven S, Smit VT, Meershoek-Klein Kranenbarg E, Hamdy NA, et al. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). Ann Oncol 2014;25:998-1004.
25. Käkönen RS, Rissanen JP, Suominen MI, Halleen JM. Quantitative image analysis method for measuring whole-body tumor burden in a mouse model of breast cancer bone metastasis. J Bone Miner Res 2008;23:S136-243.
26. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
27. Pollari S, Käkönen SM, Edgren H, Wolf M, Kohonen P, et al. Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Res Treat 2011;125:421-30.
28. Pollari S, Leivonen SK, Perälä M, Fey V, Käkönen SM, et al. Identification of microRNAs inhibiting TGF-β-induced IL-11 production in bone metastatic breast cancer cells. PLoS One 2012;7:e37361.
29. Heymann D. Bone cancer: primary bone cancers and bone metastases. 2th ed. Amsterdam: Elsevier/Academic Press; 2015. p. 486.
30. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601.
31. Haider MT, Holen I, Dear TN, Hunter K, Brown HK. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis. Bone 2014;66:240-50.
